by Steven Ertelt
August 7, 2006
Irvine, CA (LifeNews.com) — Though politicians are criticizing pro-life groups and lawmakers for opposing taxpayer funding of embryonic stem cell research, one investment relations analyst says investors wanting to put money into biotech firms should focus on those working with adult stem cells because they show better prospects.
Based in California, SmallCap Sentinel has been issuing investment information for 23 years and analyst D.R. Clark says adult stem cell research firms are a better buy.
"As the headline-grabbing battle regarding embryonic stem cell research rages, adult stem cell sources continue to provide an ever-broadening array of life-improving possibilities," Clark said in a statement LifeNews.com obtained.
"Researchers are using the far less controversial adult stem cells to attack enormous medical problems and are confident enough in their successes thus far to seek the protection of U.S. Patents," he added.
Clark said the biotech firm Medistem Laboratories has filed a patent application with the United States Patent and Trademark Office for a potential stem cell therapy for erectile dysfunction to complement a previous patent application for stem cell treatment for back problems.
While adult stem cells are yielding therapies for patients, embryonic stem cells have yet to be tried on humans because they’ve produced tumors in animals and been rejected by their immune systems.
"We’re seeing continued expansion of ideas using adult stem cells for a wide variety of medical purposes," Clark said.
Medistem Laboratories has been using adult stem cells generated from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords.
The company is working to establish a series of clinics and laboratories around the world to deliver adult stem cell-based therapies.
Related web sites:
MediStem Laboritories –